Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer

Clinical Cancer Research

Volumn 10, Issue 11, 2004, Pages 3919-3926

  Rustin, Gordon J S ^a   Bast Jr , Robert C ^b   Kelloff, Gary J ^c   Barrett, J Carl ^c   Carter, Stephen K ^d   Nisen, Perry D ^e   Sigman, Caroline C ^f   Parkinson, David R ^g   Ruddon, Raymond W ^h  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Independent Consultant   (United States)

^e ABBOTT LABORATORIES   (United States)

^f CCS Associates   (United States)

^g AMGEN INC   (United States)

^h JOHNSON AND JOHNSON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYTOSTATIC AGENT; CYTOTOXIC AGENT; PACLITAXEL;

CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

CA-125 ANTIGEN; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; DRUG DESIGN; DRUG EVALUATION; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROGNOSIS; RESEARCH DESIGN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 2542638781     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0787     Document Type: Review

References (82)

1. Brewer MA, Johnson K, Follen M, Gershenson D, Bast R Jr. Prevention of ovarian cancer: intraepithelial neoplasia. Clin Cancer Res 2003;9:20-30.
2. Bast RC Jr, Urban N, Shridhar V, et al. Early detection of ovarian cancer: promise and reality. Cancer Treat Res 2002;107:61-97.
3. Harries M, Gore M. Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol 2002;3:529-36.
4. Junor EJ, Hole DJ, Gillis CR. Management of ovarian cancer: referral to a multidisciplinary team matters. Br J Cancer 1994;70:363-70.
5. Aabo K, Adams M, Adnitt P, et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 1998;78:1479-87.
6. ICON Collaborators. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. International Collaborative Ovarian Neoplasm Study. Lancet 1998;352:1571-6.
7. Rowinsky EK, Donehower RC. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther 1991;52:35-84.
8. Trimble EL, Adams JD, Vena D, et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993;11:2405-10.
9. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 1994;12:1748-53.
10. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989;111:273-9.
11. Kohn EC, Sarosy G, Bicher A, et al. Dose-intense Taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst (Bethesda) 1994;86:18-24.
12. Einzig AI, Wiernik PH, Sasloff J, Runowicz CD, Goldberg GL. Phase II study and long-term follow-up of patients treated with Taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992;10:1748-53.
13. Gore ME, Levy V, Rustin G, et al. Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. Br J Cancer 1995;72:1016-9.
14. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
15. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (Bethesda) 2000;92:699-708.
16. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecological Oncology Group Study. J Clin Oncol 2003;21:3194-0.
17. du Bois A, Neijt JP, Thigpen JT. First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer: a new standard of care? Ann Oncol 1999;10(Suppl 1):35-41.
18. Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory Phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000;18:3084-92.
19. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002;360:505-15.
20. Kaye SB, Piccart M, Aapro M, Francis P, Kavanagh J. Phase III trials of docetaxel (Taxotere) in advanced ovarian cancer: an updated overview. Eur J Cancer 1997;33:2167-70.
21. Verschraegen CF, Sittisomwong T, Kudelka AP, et al. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol 2000;18:2733-9.
22. Vasey PA. Survival and longer-term toxicity results of the SCOTROC study: docetaxel-carboplatin (DC) vs. paclitaxel-carboplatin (PC) in epithelial ovarian cancer (EOC). Proc Am Soc Clin Oncol 2002;21:202a.
23. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
24. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
25. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-44.
26. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
27. Druker BJ. Imatinib alone and in combination for chronic myeloid leukemia. Semin Hematol 2003;40:50-8.
28. Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood 2001;98:2039-42.
29. Markman M. Why study third-, fourth-, fifth-,... line chemotherapy of ovarian cancer? Gynecol Oncol 2001;83:449-50.
30. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2000;18:106-15.
31. Zubrod CG, Schneiderman SM, Frei E III, et al. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide J Chronic Dis 1960;11:7-33.
32. Gehan EA, Schneiderman MA. Historical and methodological developments in clinical trials at the National Cancer Institute. Stat Med 1990;9:871-80; discussion 903-6.
33. WHO handbook for reporting results of cancer treatment. Geneva: WHO; 1979.
34. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer (Phila) 1981;47:207-14.
35. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
36. Ozols R, Schwartz P, Eifel P. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott; 1997. p. 1502-39.
37. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (Bethesda) 2000;92:205-16.
38. Bast RC Jr, Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Investig 1981; 68:1331-7.
39. Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-7.
40. O'Brien TJ, Tanimoto H, Konishi I, Gee M. More than 15 years of CA 125: what is known about the antigen, its structure and its function. Int J Biol Markers 1998;13:188-95.
41. Bast RC Jr, Xu FJ, Yu YH, et al. CA 125: the past and the future. Int J Biol Markers 1998;13:179-87.
42. Nustad K, Bast RC Jr, Brien TJ, et al. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop International Society for Oncodevelopmental Biology and Medicine. Tumour Biol 1996;17:196-219.
43. Tamakoshi K, Kikkawa F, Hasegawa N, et al. Clinical value of a new serum tumor marker, CA125II, in gynecologic disease: comparison with CA125. Gynecol Obstet Investig 1995;39:125-9.
44. Davelaar EM, van Kamp GJ, Verstraeten RA, Kenemans P. Comparison of seven immunoassays for the quantification of CA 125 antigen in serum. Clin Chem 1998;44:1417-22.
45. Kenemans P, Verstraeten AA, van Kamp GJ, von Mensdorff-Pouilly S. The second generation CA 125 assays. Ann Med 1995;27: 107-13.
46. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989;4:1-12.
47. Meden H, Fattahi-Meibodi A. CA 125 in benign gynecological conditions. Int J Biol Markers 1998;13:231-7.
48. Grover S, Koh H, Weideman P, Quinn MA. The effect of the menstrual cycle on serum CA 125 levels: a population study. Am J Obstet Gynecol 1992;167:1379-81.
49. Hawkins RE, Roberts K, Wiltshaw E, et al. The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynaecol 1989;96:1395-9.
50. Hogberg T, Kagedal B. Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma. Acta Obstet Gynecol Scand 1990;69:423-9.
51. van der Burg ME, Lammes FB, van Putten WL, Stoter G. Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy. Gynecol Oncol 1988;30:307-12.
52. Devine PL, McGuckin MA, Quin RJ, Ward BG. Predictive value of the combination of serum markers, CA125, CASA and TPS in ovarian cancer. Int J Gynecol Cancer 1995;5:170-8.
53. Nagele F, Petru E, Medl M, et al. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1995;86:259-64.
54. Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev 1995; 21:215-45.
55. Fayers PM, Rustin G, Wood R, et al. The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer. Int J Gynecol Cancer 1993;3:285-92.
56. van Dalen A, Favier J, Burges A, et al. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol 2000;79:444-50.
57. Hogdall CK, Norgaard-Pedersen B, Mogensen O. The prognostic value of pre-operative serum tetranectin, CA-125 and a combined index in women with primary ovarian cancer. Anticancer Res 2002;22:1765-8.
58. Yedema CA, Kenemans P, Voorhorst F, et al. CA 125 half-life in ovarian cancer: a multivariate survival analysis. Br J Cancer 1993;67: 1361-7.
59. Hunter VJ, Daly L, Helms M, et al. The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol 1990;163:1164-7.
60. Rustin GJ, Gennings JN, Nelstrop AE, et al. Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group. J Clin Oncol 1989;7:1667-71.
61. van der Burg ME, Lammes FB, Verweij J. CA 125 in ovarian cancer. Neth J Med 1992;40:36-51.
62. Rustin GJ, Nelstrop AE, McClean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996;14:1545-51.
63. Rustin GJ, Nelstrop AE, Bentzen SM, Bond SJ, McClean P. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in Phase II trials. J Clin Oncol 2000;18:1733-9.
64. Bridgewater JA, Nelstrop AE, Rustin GJ, et al. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol 1999;17:501-8.
65. Pearl ML, Yashar CM, Johnston CM, Reynolds RK, Roberts JA. Exponential regression of CA 125 during salvage treatment of ovarian cancer with taxol. Gynecol Oncol 1994;53:339-43.
66. Davelaar EM, Bonfrer JM, Verstraeten RA, ten Bokkel Huinink WW, Kenemans P. CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel? Cancer (Phila) 1996;78:118-27.
67. Rustin GJ, Nelstrop AE, Crawford M, et al. Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. J Clin Oncol 1997;15:172-6.
68. Meyer T, Nelstrop AE, Mahmoudi M, Rustin GJ. Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer. Ann Oncol 2001;12:1705-9.
69. Benedetti Panici P, Greggi S, Amoroso M, et al. A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: results of a Phase II study. Int J Gynecol Cancer 2001;11:438-44.
70. Guppy AE, Rustin GJ. CA125 response: can it replace the traditional response criteria in ovarian cancer? Oncologist 2002;7: 437-43.
71. van der Burg ME, Lammes FB, Verweij J. The role of CA 125 and conventional examinations in diagnosing progressive carcinoma of the ovary. Surg Gynecol Obstet 1993;176:310-14.
72. Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 1996;7:361-4.
73. Rustin GJ, Nelstrop AE, Bentzen SM, Piccart MJ, Bertelsen, K. Use of tumour markers in monitoring the course of ovarian cancer. Ann Oncol 1999;10(Suppl 1):21-7.
74. van der Burg ME, Lammes FB, Verweij J. The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. Ann Oncol 1990;1:301-2.
75. Krebs HB, Goplerud DR, Kilpatrick SJ, Myers MB, Hunt A. Role of Ca 125 as tumor marker in ovarian carcinoma. Obstet Gynecol 1986;67:473-7.
76. Rustin GJ, Marples M, Nelstrop AE, Mahmoudi M, Meyer T. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 2001;19:4054-7.
77. Rustin GJ. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 2003;21:187-193.
78. Vergote I, Rustin GJ, Eisenhauer EA, et al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst (Bethesda) 2000;92: 1534-5.
79. Rustin GJ, Quinnell TG, Johnson J, et al. Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer. Br J Cancer 1996;74:1479-81.
80. Gore M, A'Hern R, Stankiewicz M, Slevin M. Tumour marker levels during marimastat therapy. Lancet 1996;348:263-4.
81. Skates SJ, Menon U, MacDonald N, et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003;21:206-10.
82. Markman M. The myth of measurable disease in ovarian cancer. J Clin Oncol 2003;21:3013-5.